<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01324440</url>
  </required_header>
  <id_info>
    <org_study_id>V710-002</org_study_id>
    <nct_id>NCT01324440</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With Merck Aluminum Adjuvant or Without Merck Aluminum Adjuvant in Healthy Adults 18 to 70 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety, tolerability, and immunogenicity of the
      Merck 0657nI S. aureus vaccine (V710) either with or without Merck Aluminum Adjuvant (MAA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Positive Immune Response, Defined as a Change in Antibody Level Greater Than or Equal to a 2-fold-rise at Day 14 Compared to Baseline</measure>
    <time_frame>Baseline and Day 14 postvaccination</time_frame>
    <description>Immunoglobulin G (IgG) antibodies were measured by a LUMINEX(TM) assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentrations (GMC)</measure>
    <time_frame>Day 14 postvaccination</time_frame>
    <description>Immunoglobulin G (IgG) antibodies were measured by a LUMINEX(TM) assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Antibody Concentration (Titer) at Day 14 Compared to Baseline, Expressed as the Geometric Mean Fold-rise (GMFR)</measure>
    <time_frame>Baseline and Day 14 postvaccination</time_frame>
    <description>Immunoglobulin G (IgG) antibodies were measured by a LUMINEX(TM) assay.
The GMFR is the ratio of the antibody concentration at Day 14 to the antibody concentration at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Vaccine-related Serious Adverse Experiences</measure>
    <time_frame>Up to Day 360 postvaccination</time_frame>
    <description>Investigators were instructed to determine the seriousness and causality (relatedness to test vaccine) of each AE based on criteria defined in the protocol:
A serious adverse event (SAE) is any AE that:
results in death,
is life threatening,
results in a persistent or significant disability/incapacity,
results in or prolongs an existing inpatient hospitalization,
is a congenital anomaly/birth defect,
is a cancer,
is an overdose,
or is another important medical event that may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Staphylococcal Infections</condition>
  <arm_group>
    <arm_group_label>V710 without MAA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>V710 with MAA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V710 (30 µg) with MAA</intervention_name>
    <description>Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly</description>
    <arm_group_label>V710 with MAA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V710 (30 µg) without MAA</intervention_name>
    <description>Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly</description>
    <arm_group_label>V710 without MAA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Participant was in good physical health

          -  Participant was able to understand study procedures and agreed to participate in the
             study by providing written informed consent.

          -  Participant was willing and able to participate in the entire study duration planned
             for up to 12 months (~360 days).

          -  Female participants of reproductive potential were required to have a negative urine
             pregnancy test immediately prior to study vaccination. Female participants of
             reproductive potential must have used an acceptable method of birth control for 2
             weeks prior to enrollment, and agreed to use an acceptable method of birth control for
             1 month after vaccination.

        Exclusion criteria:

          -  Participant suffered from a chronic skin condition that predisposed the individual to
             the development of chronic skin or soft-tissue infections (e.g., psoriasis, chronic
             granulomatous disease, atopic dermatitis).

          -  Participant developed a serious infection (e.g., bacteremia, pneumonia, mediastinitis)
             attributed to S. aureus in the 12 months prior to screening.

          -  Participant had a history of anaphylaxis to aluminum-containing adjuvant or other
             vaccine components.

          -  Participant had a temperature of ≥100.4ºF (≥38.0ºC), oral equivalent, within 48 hours
             prior to receipt of V710.

          -  Participant had received a live virus vaccine within 30 days prior to receipt of V710
             or was scheduled to receive vaccination with a live virus vaccine within 30 days
             following study entry.

          -  Participant had received any other licensed vaccine (including non-live virus
             vaccines) within 14 days prior to receipt of V710 or was scheduled to receive any
             other licensed vaccine (including non-live virus vaccines) within 30 days following
             study entry.

          -  Participant had received V710 in a prior clinical study (Merck V710 Protocol 001).

          -  Participant was administered immunoglobulin or blood product within 90 days prior to
             receipt of V710 or was scheduled to receive such products within 30 days following
             study entry.

          -  Participant had received treatment with systemic (intramuscular, oral, or intravenous)
             corticosteroids or another immunosuppressive medication (e.g., calcineurin inhibitors,
             mycophenolate, azathioprine) or biological agents (e.g., rituximab) in the 14 days
             prior to receipt of V710 or was anticipated to receive such medications for a chronic
             medical condition during the course of the study.

          -  Participant had a condition that required active medical intervention or monitoring to
             avert serious danger to the participant's health or well-being, such as diabetes
             mellitus, autoimmune disease, or clinically significant chronic medical conditions
             that were considered progressive, including but not limited to: coronary artery
             disease, congestive heart failure, cardiomyopathy, progressive valvular heart disease,
             chronic obstructive pulmonary disease, pulmonary fibrosis, active peptic ulcer
             disease, chronic renal disease, chronic hepatic disease, multiple sclerosis,
             progressive neuropathies, or seizure disorder requiring therapy in the past 3 years.

          -  Participant had known or suspected impairment of immunologic function including, but
             not limited to, the following conditions: autoimmune disease, diabetes mellitus,
             endstage renal disease, hepatic insufficiency/cirrhosis, splenectomy, or human
             immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).

          -  Participant had a condition in which repeated venipuncture or injections posed more
             than minimal risk for the subject, such as hemophilia, other severe coagulation
             disorders, or significantly impaired venous access.

          -  Participant was pregnant or breastfeeding, or planning to conceive within the 12-month
             study duration period.

          -  Participant had clinically significant abnormalities based on the participant or
             physical examination.

          -  Participant had recent history (within the past 5 years) or current evidence of drug
             or alcohol abuse.

          -  Participant had a major psychiatric illness, including any history of schizophrenia or
             severe psychosis, bipolar disorder requiring therapy, or any subject with suicidal
             ideation within the previous 3 years.

          -  Participant was legally or mentally incapacitated.

          -  Participant had participated in another clinical study in the past 4 weeks, or
             participant planned to participate in a treatment-based study or study in which an
             invasive procedure was to be performed during the first 3 months of this study
             (through Day 84).

          -  Participant had a history of any condition which, in the opinion of the investigator,
             posed an additional risk for the subject or confounded the results of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Harro CD, Betts RF, Hartzel JS, Onorato MT, Lipka J, Smugar SS, Kartsonis NA. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies. Vaccine. 2012 Feb 21;30(9):1729-36. doi: 10.1016/j.vaccine.2011.12.045. Epub 2011 Dec 20.</citation>
    <PMID>22192849</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <results_first_submitted>September 9, 2011</results_first_submitted>
  <results_first_submitted_qc>September 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 17, 2011</results_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacterial Vaccines</keyword>
  <keyword>Staphylococcus Aureus</keyword>
  <keyword>Adjuvanted Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>V710 With MAA</title>
          <description>Single 0.5-mL injection (30-µg) dose of V710 with MAA, intramuscularly.</description>
        </group>
        <group group_id="P2">
          <title>V710 Without MAA</title>
          <description>Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>V710 With MAA</title>
          <description>Single 0.5-mL injection (30-µg) dose of V710 with MAA, intramuscularly.</description>
        </group>
        <group group_id="B2">
          <title>V710 Without MAA</title>
          <description>Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>17 and under</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 to 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 to 69</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Over 69</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Positive Immune Response, Defined as a Change in Antibody Level Greater Than or Equal to a 2-fold-rise at Day 14 Compared to Baseline</title>
        <description>Immunoglobulin G (IgG) antibodies were measured by a LUMINEX(TM) assay.</description>
        <time_frame>Baseline and Day 14 postvaccination</time_frame>
        <population>The per-protocol analysis excluded patients who had missing baseline and/or postvaccination (Day 14) serology data and patients who developed a S. aureus infection during the 14 days postvaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V710 With MAA</title>
            <description>Single 0.5-mL injection (30-µg) dose of V710 with MAA, intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>V710 Without MAA</title>
            <description>Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Positive Immune Response, Defined as a Change in Antibody Level Greater Than or Equal to a 2-fold-rise at Day 14 Compared to Baseline</title>
          <description>Immunoglobulin G (IgG) antibodies were measured by a LUMINEX(TM) assay.</description>
          <population>The per-protocol analysis excluded patients who had missing baseline and/or postvaccination (Day 14) serology data and patients who developed a S. aureus infection during the 14 days postvaccination.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentrations (GMC)</title>
        <description>Immunoglobulin G (IgG) antibodies were measured by a LUMINEX(TM) assay.</description>
        <time_frame>Day 14 postvaccination</time_frame>
        <population>The per-protocol analysis excluded patients who had missing baseline and/or postvaccination (Day 14) serology data and patients who developed a S. aureus infection during the 14 days postvaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V710 With MAA</title>
            <description>Single 0.5-mL injection (30-µg) dose of V710 with MAA, intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>V710 Without MAA</title>
            <description>Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations (GMC)</title>
          <description>Immunoglobulin G (IgG) antibodies were measured by a LUMINEX(TM) assay.</description>
          <population>The per-protocol analysis excluded patients who had missing baseline and/or postvaccination (Day 14) serology data and patients who developed a S. aureus infection during the 14 days postvaccination.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.4" lower_limit="82.9" upper_limit="160.6"/>
                    <measurement group_id="O2" value="99.1" lower_limit="73.5" upper_limit="133.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Antibody Concentration (Titer) at Day 14 Compared to Baseline, Expressed as the Geometric Mean Fold-rise (GMFR)</title>
        <description>Immunoglobulin G (IgG) antibodies were measured by a LUMINEX(TM) assay.
The GMFR is the ratio of the antibody concentration at Day 14 to the antibody concentration at baseline.</description>
        <time_frame>Baseline and Day 14 postvaccination</time_frame>
        <population>The per-protocol analysis excluded patients who had missing baseline and/or postvaccination (Day 14) serology data and patients who developed a S. aureus infection during the 14 days postvaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V710 With MAA</title>
            <description>Single 0.5-mL injection (30-µg) dose of V710 with MAA, intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>V710 Without MAA</title>
            <description>Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Antibody Concentration (Titer) at Day 14 Compared to Baseline, Expressed as the Geometric Mean Fold-rise (GMFR)</title>
          <description>Immunoglobulin G (IgG) antibodies were measured by a LUMINEX(TM) assay.
The GMFR is the ratio of the antibody concentration at Day 14 to the antibody concentration at baseline.</description>
          <population>The per-protocol analysis excluded patients who had missing baseline and/or postvaccination (Day 14) serology data and patients who developed a S. aureus infection during the 14 days postvaccination.</population>
          <units>ratio of IgG titer at Day 14 to baseline</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="3.3" upper_limit="6.1"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2.9" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Vaccine-related Serious Adverse Experiences</title>
        <description>Investigators were instructed to determine the seriousness and causality (relatedness to test vaccine) of each AE based on criteria defined in the protocol:
A serious adverse event (SAE) is any AE that:
results in death,
is life threatening,
results in a persistent or significant disability/incapacity,
results in or prolongs an existing inpatient hospitalization,
is a congenital anomaly/birth defect,
is a cancer,
is an overdose,
or is another important medical event that may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
        <time_frame>Up to Day 360 postvaccination</time_frame>
        <population>Any subject who received clinical material and had at least 1 day of safety follow-up was included in the safety summary.</population>
        <group_list>
          <group group_id="O1">
            <title>V710 With MAA</title>
            <description>Single 0.5-mL injection (30-µg) dose of V710 with MAA, intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>V710 Without MAA</title>
            <description>Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Vaccine-related Serious Adverse Experiences</title>
          <description>Investigators were instructed to determine the seriousness and causality (relatedness to test vaccine) of each AE based on criteria defined in the protocol:
A serious adverse event (SAE) is any AE that:
results in death,
is life threatening,
results in a persistent or significant disability/incapacity,
results in or prolongs an existing inpatient hospitalization,
is a congenital anomaly/birth defect,
is a cancer,
is an overdose,
or is another important medical event that may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
          <population>Any subject who received clinical material and had at least 1 day of safety follow-up was included in the safety summary.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>V710 With MAA</title>
          <description>Single 0.5-mL injection (30-µg) dose of V710 with MAA, intramuscularly.</description>
        </group>
        <group group_id="E2">
          <title>V710 Without MAA</title>
          <description>Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

